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MicroRnA and transcription 
factor co-regulatory networks and 
subtype classification of seminoma 
and non-seminoma in testicular 
germ cell tumors
Guimin Qin1,4,6, Saurav Mallik1,6, Ramkrishna Mitra2, Aimin Li1,3, Peilin Jia1, Christine M. eischen2 
& Zhongming Zhao1,5*
Recent studies have revealed that feed-forward loops (FFLs) as regulatory motifs have synergistic roles 
in cellular systems and their disruption may cause diseases including cancer. FFLs may include two 
regulators such as transcription factors (TFs) and microRNAs (miRNAs). In this study, we extensively 
investigated TF and miRNA regulation pairs, their FFLs, and TF-miRNA mediated regulatory networks 
in two major types of testicular germ cell tumors (TGCT): seminoma (SE) and non-seminoma (NSE). 
Specifically, we identified differentially expressed mRNA genes and miRNAs in 103 tumors using the 
transcriptomic data from The Cancer Genome Atlas. Next, we determined significantly correlated TF-
gene/miRNA and miRNA-gene/TF pairs with regulation direction. Subsequently, we determined 288 
and 664 dysregulated TF-miRNA-gene FFLs in SE and NSE, respectively. By constructing dysregulated 
FFL networks, we found that many hub nodes (12 out of 30 for SE and 8 out of 32 for NSE) in the top 
ranked FFLs could predict subtype-classification (Random Forest classifier, average accuracy ≥90%). 
These hub molecules were validated by an independent dataset. Our network analysis pinpointed 
several SE-specific dysregulated miRNAs (miR-200c-3p, miR-25-3p, and miR-302a-3p) and genes 
(EPHA2, JUN, KLF4, PLXDC2, RND3, SPI1, and TIMP3) and NSE-specific dysregulated miRNAs (miR-
367-3p, miR-519d-3p, and miR-96-5p) and genes (NR2F1 and NR2F2). This study is the first systematic 
investigation of TF and miRNA regulation and their co-regulation in two major TGCT subtypes.
Testicular germ cell tumors (TGCT) occur most frequently in men between ages of 20 and 401,2. Accordingly 
to histology, TGCT can be separated into two major types: seminoma (SE) and non-seminoma (NSE)1–4, and 
NSE has several subtypes. While the etiology of the two TGCT subtypes is well studied, their molecular profiles, 
signature genetic markers, and regulatory mechanisms have not been systematically investigated, unlike other 
common cancers. Such an investigation is much needed now to identify molecular signatures either common in 
two subtypes, or unique in subtype. The molecular signatures may be further useful for clinical implications, such 
as patient stratification and subtype-based or personalized treatment. Currently, there are several challenges in 
TGCT treatment. First, TGCT patients have a high risk of relapse with poor prognosis. Second, there are severe 
side effects for current chemotherapy and radiotherapy that lead to development of other pathologies. Third, 
since most of the patients are adolescent or young men, there is a heavy burden for the patients and families in 
the long run2,3.
During the last decade, a number of studies have been conducted to explore insights into the genetic, epi-
genetic, and molecular mechanisms of TGCT. For example, after collecting TGCT related genes from previous 
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studies (e.g., CCT6A, IGFBP3 and SALL2 as novel, and KRAS, MYCN, and TPD52 as known), Alagaratnam et al. 
analyzed the differentially expressed genes and identified a gene signature for each subtype5. Litchfield et al. 
performed a systematic review of the genomic features of TGCT from a timeline perspective and suggested gene 
biomarkers for the different stages3. The authors summarized 25 risk loci from previous studies and identified 19 
new risk loci to TGCT by analyzing the GWAS data6. TGCT-related genes and miRNAs were reported from two 
epigenetic alteration studies2,7. Recently, Facchini et al. discussed the genetic and epigenetic events associated 
with TGCT, as well as the molecular mechanisms of TGCT8. Furthermore, integrated genomic analysis of TGCT, 
including expression profiles, DNA methylation, somatic copy number variation, was recently performed4. 
Among the studies, telomere length (TL) was determined to be unique in TGCT and its two types (SE and NSE)9. 
Further analysis revealed that TL elongation was dominant in NSE, while TL shortening was common in SE10. 
The TGCT type-specific molecular profiles related to TL were explored using the expression data of mRNA and 
microRNA (miRNA), a type of short non-coding RNA (21–22 nucleotides) that targets mRNAs11,12, generated 
by The Cancer Genome Atlas (TCGA)10. In that study, the authors determined that both mRNA and miRNA 
expression profiles could clearly distinguish these two types. TGCT-related genes and miRNAs were also reported 
from two epigenetic alteration studies2,7. Since miRNAs have a key role in post-transcriptional regulation of gene 
expression, it is important to further explore how genes are synergistically regulated in both types, leading to the 
elucidation of possible regulatory modules and mechanisms unique in NSE or SE.
Gene regulation is a basic mechanism in biological processes. It is dynamic and complex. Disruption of gene 
expression regulation may lead to human disease or abnormal phenotypes. Transcription factors (TFs) and miR-
NAs are two important types of gene expression regulators: TFs regulate gene expression at the transcriptional 
level by binding the promoter regions while miRNAs at the post-transcriptional level by binding the 3′ untrans-
lated regions. Both TF and miRNA regulation can be oncogenic or tumor-suppressive13. Importantly, TFs and 
miRNAs can regulate each other. When they co-regulate a common target gene, they form a feed-forward loop 
(FFL). FFLs are important regulatory units, which can further form gene regulatory networks. So far, the dys-
regulated TF-miRNA-mediated FFLs have been found in several complex diseases, including schizophrenia14, 
glioblastoma15, T-cell acute lymphoblastic leukemia16, ovarian cancer17, lung cancer18, prostate cancer19, pan-
creatic cancer20, myocardial infarction21, colorectal cancer22, and dental diseases (cleft lip and cleft palate)23,24. 
Yan et al. proposed a method, called dChip-GemiNI, to identify common (matched) and specific TF-miRNA 
FFLs among five cancer types25. A more comprehensive TF-miRNA regulation analysis in pan-cancer data 
revealed 26 dysregulated FFLs in 13 cancer types, and predicted candidate genes and drug targets26. Zhang 
et al. determined potential active miRNA-TF-gene regulatory pathways in obesity-related inflammation using 
network-based methods27. Guo et al. investigated the distinct regulatory roles of TFs and miRNAs from gene reg-
ulatory network perspective, and explored the data from ENCODE (Encyclopedia of DNA Elements) and GTEx 
(Genotype-Tissue Expression)28. Furthermore, several studies introduced motif or module detection methods 
and performed TF-miRNA-gene regulatory network analysis29–34. Thus far, there has been no systematic analysis 
of TF and miRNA regulatory FFLs in TGCT.
Here, we compared mRNA and miRNA gene expression in NSE versus SE. We identified differentially 
expressed mRNAs and miRNAs by using tool Limma35,36. We also collected TF-gene/miRNA pairs and 
miRNA-gene/TF pairs. Based on these intermediate results, we formed FFLs. These FFLs were used to construct 
TF-miRNA-target gene regulatory network in NSE and SE, respectively. Follow-up network characteristics analy-
sis (e.g., hub nodes for TFs, miRNAs, genes) and subtype classification analysis unveiled a subset of the FFLs that 
might have pathogenic potential in TGCT. Finally, these significant miRNAs and genes were evaluated using an 
independent dataset for TGCT. Our study is the first systematic investigation of TF and miRNA regulation as well 
as their co-regulation in two major TGCT subtypes, NSE and SE. The analytical approaches provided an efficient 
way to identify significant molecules associated with TGCT.
Results
Identification of differentially expressed TFs, miRNAs, and genes. Figure 1 summarizes our work-
flow, in which we integrated regulation pairs and gene expression profiles from different data sources, identified 
FFLs, and constructed and analyzed disease-specific gene regulatory networks. By following the steps described 
in the Materials and methods section, we identified 2,950 highly expressed genes and 167 significantly overex-
pressed miRNAs in NSE tumor samples (n = 48) versus SE tumor samples (n = 55) (>2 fold-change, adjusted 
p-value < 0.05). In parallel, we determined 1,969 significantly overexpressed genes and 58 highly expressed miR-
NAs in SE versus NSE samples (>2 fold-change, adjusted p-value < 0.05). In this study, we called these genes as 
differentially expressed genes in NSE or SE. We combined all the differentially expressed genes to identify regula-
tory interactions between the regulators and predicted targets.
Regulatory interactions among TFs, miRNAs, and genes. Using the TRANSFAC data37 and its 
implemented method, MATCH38, we identified 56,678 TF-target gene pairs where TFs and genes were differ-
entially expressed. We obtained 11,320 differentially expressed miRNA-target pairs using four miRNA target 
databases (TargetScan39, miRanda40, PITA41, and miRTarBase42). Based on these pairs, we applied Pearson's cor-
relation coefficient (PCC) between regulators (TFs or miRNAs) and target genes, which resulted in a total of 952 
FFLs with statistical significance (p-value < 0.05).
In NSE, we obtained 6,350 regulation pairs covering 127 unique TFs, 142 unique miRNAs, and 1,537 unique 
genes (Table 1). In SE versus NSE analysis, we determined 7,447 regulation pairs containing 152 unique TFs, 170 
unique miRNAs, and 2,049 unique genes (Table 1). As summarized in Table 1, the activation regulation refers 
to the positive correlation between TFs and their targets (genes and miRNAs), while the repression regulation 
refers to the negative correlation between TFs and their targets, as well as between miRNAs and their targets (we 
only used negative regulation for miRNA-targets due to its regulation mechanism). As shown in Tables 1, 84.4% 
3Scientific RepoRtS |          (2020) 10:852  | https://doi.org/10.1038/s41598-020-57834-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
(5,362/6,350) and 93.1% (6,930/7,447) of regulation pairs were TF-target regulations for NSE-specific analysis 
and SE-specific analysis, respectively. Among them, ~68% were determined to be positively correlated for both 
NSE-specific analysis and SE-specific analysis (3,669/5,362 = 68.43%, and 4,699/6,930 = 67.81%, respectively).
TF-miRNA mediated feed-forward loops in SE and NSE. We identified three types of coherent 
FFLs in the TF-miRNA mediated gene regulatory networks (Supplementary file S1). Such coherent FFLs could 
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Figure 1. Overview of the flowchart. (A) mRNA and miRNA expression profiles for NSE and SE. (B) Predicted 
TF/miRNA-target pairs. (C) Subtype-specific regulation pairs. (D) Feed-forward loop (FFL) models. (E) 
Subtype-specific regulatory networks and hub detection. (Microsoft Visio 2016; RStudio version 1.1.383, 
https://rstudio.com/; Cytoscape version 3.7.1, https://cytoscape.org/).
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reduce false positive interactions, a common issue in regulatory analysis at large-scale43. Specifically, they are TF 
repressed FFLs (TRFs), TF activated FFLs (TAFs), and miRNA repressed FFLs (MRFs). As summarized in Table 2, 
we identified 164 TRFs, 386 TAFs and 114 MRFs in NSE, and 86 TRFs, 163 TAFs, and 39 MRFs in SE. Although 
they had similar number of significant regulations (6,350 regulation pairs in NSE, and 7,447 regulation pairs in 
SE), the frequency of FFLs in NSE was more than twice that in SE (Hypergeometric test, p-value = 4.76 × 10−53). 
For example, 386 out of 664 FFLs were TAFs in NSE while for SE, 163 out of 288 FFLs were TAFs. Besides, we 
found only a few FFLs shared by these two subtypes, i.e. 1 shared TRF, 16 TAFs, and 5 MRFs.
We examined the number of different categories of FFLs for the top ten TFs and miRNAs (Supplementary 
Fig. S1). In NSE, we determined 5 TF-coding genes (KLF4, LHX3, MAFA, NANOG, and POU5F1) that had a 
significant role in creating TRFs, while other TF-coding genes (ERG, FOXC1, JUN, NR2F1, NR2F2, etc.) were 
involved in TAFs and MRFs. The top 5 TF-coding genes (FOXC1, ERG, and NR2F2) formed 68, 65, and 63 FFLs, 
respectively, accounting for 30% of the total FFLs. Among the top 10 miRNAs, miR-96-5p and miR-519d-3p were 
involved in 95 and 83 FFLs, accounting for 14.3% (95/664) and 12.5% (83/664) of the total number of FFLs. In 
SE, we identified that SPI1, KLF4, and JUN were in the top 3 list, which formed 59, 48, and 32 FFLs, respectively. 
These 3 TFs accounted for 48% of the total FFLs. For the 3 top TF-coding genes, SPI1 was involved in 44 TAFs, 
and 15 TRFs, while KLF4 formed 39 TRFs, 5 TAFs, and 4 MRFs, respectively. In these top 10 TFs of NSE and 
SE, there were only 2 overlapping TF-coding genes (JUN, and NR2F2). The top 10 miRNAs were miR-141-3p, 
miR-25-3p, miR-200c-3p, miR-29b-3p, miR-302a-3p, miR-96-5p, miR-182-5p, miR-367-3p, miR-372-3p, and 
miR-373-3p. The top 3 miRNAs (miR-141-3p, miR-25-3p, and miR-200c-3p) formed 32, 27, and 25 FFLs, and 
accounted for 11.1% (32/288), 9.4% (27/288), and 8.7% (25/288) of the total number of FFLs, respectively. In 
addition, among the lists of top 10 miRNAs for NSE and SE, we obtained 5 common miRNAs (miR-182-5p, miR-
302a-3p, miR-367-3p, miR-373-3p, and miR-96-5p) that might have greater impact on TGCT.
Common and subtype-specific regulatory networks. Topological properties of regulatory net-
works. We constructed miRNA and TF mediated regulatory networks in two TGCT subtypes from the identi-
fied regulation pairs (Table 1). The NSE-specific regulatory network contained 194 nodes (44 TFs, 23 miRNAs, 
and 127 genes) and 834 links while the SE-specific regulatory network had 168 nodes (41 TFs, 35 miRNAs, and 
92 genes) and 508 links. The average degrees were 8.5 and 5.9 in these two networks, respectively. Therefore, the 
NSE-specific regulatory network was more strongly connected than the SE-specific regulatory network. This 
feature, plus more nodes and edges, indicated that NSE was more complex than SE in its regulatory mechanism. 
This feature might also reflect more heterogeneous samples of NSE than SE. Since the regulatory networks were 
directed networks, we investigated their out-degree distribution, in-degree distribution, and clustering coefficient 
distribution (Supplementary Fig. S2A,B). We determined that most molecules had small out-degrees and only a 
few genes had high out-degrees for both NSE and SE specific networks. TFs and miRNAs regulated target genes, 
and also regulated each other, but only a few TFs and miRNAs regulated a large number of targets. One difference 
Subtype Regulation pair Regulation type # pairs # miRNAs # TFs # genes
NSE
TF-gene Activation 2,951 — 113 1,266
Repression 1,013 — 77 576
TF-miRNA Activation 718 133 85 —
Repression 680 86 52 —
miRNA-gene Repression 907 39 — 299
miRNA-TF Repression 81 17 19 —
SE TF-gene Activation 4,150 — 137 1,686
Repression 1,764 — 113 1,050
TF-miRNA Activation 549 156 81 —
Repression 467 125 74 —
miRNA-gene Repression 463 58 — 232
miRNA-TF Repression 54 24 34 —
Table 1. Summary of miRNA and TF-mediated regulations in NSE and SE. Note: ‘—’ denotes no observation.
Subtype FFL model # FFLs
# nodes # links
TFs miRNAs genes TF-gene TF-miRNA miRNA-gene miRNA-TF
NSE TRF 164 17 19 55 73 69 127 —
TAF 386 26 19 101 195 102 237 —
MRF 114 12 14 52 58 — 105 36
SE TRF 86 16 28 51 60 44 78 —
TAF 163 28 26 66 118 76 116 —
MRF 39 17 13 28 34 — 35 24
Table 2. Summary of feed-forward loops (FFLs). Note: abbreviations are described in main text.
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between NSE and SE is that NSE had more nodes with the out-degree greater than 20. The in-degree values were 
more evenly distributed than those out-degree values. In addition, we determined that their average clustering 
coefficient distributions were similar. There were only four nodes having an average clustering coefficient greater 
than 0.2 for both subtypes. We searched the reported TGCT-related genes and miRNAs in related databases, 
including OMIM44, COSMIC45, candidate caused TGCT genes from Litchfield et. al.6, HMDD46, miR2Disease47, 
and PhenomiR48. Only 1 gene GAB2 was regulated in our FFLs, 5 and 10 related miRNAs were found in our FFLs 
for NSE and SE, respectively (Supplementary file S2).
Hubs in the regulatory networks modulate crucial functions in TGCT tumorigenesis. Following the definition of 
hubs in Yu et al.49, we searched the hubs (TFs, miRNAs, and genes) in the regulatory networks by both out-degree 
and in-degree of nodes. We identified 32 hubs (5 TFs, 13 miRNAs, and 14 genes) and 30 hubs (8 TFs, 9 miRNAs, 
and 13 genes) in NSE and SE subtype-specific regulatory networks, respectively (Supplementary Table S1). There 
were 4 NSE-specific hub TFs (ERG, FOXC1, NR2F1, and NR2F2), 7 SE-specific hub TFs (GATA3, IRF8, KLF4, 
SOX9, SPI1, STAT6, and TFAP2C), as well as 1 common hub TF (JUN). Among these 5 TFs obtained from the 
NSE network, 2 TFs (ERG and JUN) were oncogenes, while 5 (GATA3, JUN, KLF4, SOX9, and STAT6) of the 8 
hub TFs obtained from SE-specific network were oncogenes.
All of the hub miRNAs were determined from the top miRNAs. For NSE subtype, all of the 13 miRNAs 
belonged to four miRNA clusters: miR-183/182/96 cluster (miR-96-5p, and miR-182-5p), miR-302/367 clus-
ter (miR-302a-3p, miR-302d-3p, and miR-367-3p), C19MC cluster (miR-519d-3p, miR-520a-3p, miR-520b, 
miR-520c-3p, miR-520d-3p, and miR-520e), and miR-371-3 cluster (miR-372-3p, and miR-373-3p). Of note, 9 
miRNAs (miR-302a-3p, miR-302d-3p, miR-372-3p, miR-373-3p, miR-520a-3p, miR-520b, miR-520c-3p, miR-
520d-3p, and miR-520e) were members of a miRNA family, miR-301/372/373/520. For the SE-specific network, 
the 9 hub miRNAs involved in 6 miRNA clusters: miR-106b-25/miR-17-92 clusters (miR-25-3p), miR-29 cluster 
(miR-29b-3p), miR-141/200c cluster (miR-141-3p, and miR-200c-3p), miR-183/182/96 cluster (miR-96-5p, and 
miR-182-5p), miR-302/367 cluster (miR-302a-3p, and miR-367-3p), and miR-371-3 cluster (miR-372-3p).
The miRNAs in the miR-183/182/96, miR-302/367 and miR-371-3 clusters were enriched in both NSE and SE. 
On the other hand, the miRNAs in C19MC cluster were enriched in the NSE type only, and the miRNAs in miR-
141/200c cluster were enriched in the SE type only. We investigated the miRNAs at the cluster level. The miR-
183/182/96 cluster consisted of miR-96, miR-182, and miR-183, which shared almost identical seed sequences. 
The miRNAs in this cluster act as oncomiRs across cancer types, including prostate, breast, and ovary cancers50. 
Furthermore, these miRNAs have an important role in regulating major cellular pathways in cancer, including 
apoptosis, DNA repair, metabolism, and others50. In our previous study, we reported that miR-96-5p and miR-
183-5p were overexpressed across 12 cancer types (not including TGCT)26. In this work, we determined that 
miR-182-5p and miR-96-5p were significantly overexpressed (with fold-change 3.62 and 3.94, adjusted p-value 
6.45 × 10−8 and 8.45 × 10−10, respectively) in the SE samples versus the NSE samples, and they were involved 
in 149 and 34 FFLs in NSE and SE, respectively. This observation indicated that they might have important 
regulatory roles in the pathology of TGCT. The miR-302/367 cluster consisted of 5 miRNAs (miR-302a, miR-
302b, miR-302c, miR-302d, and miRNA-367), which were demonstrated to have vital roles in various biological 
processes and cellular signaling pathways51. The miRNAs in this cluster were activated by some TFs, including 
GATA6, POU5F1, NANOG, and SOX251, and were related to TGCT2,47,52. The C19MC cluster (chromosome 19 
miRNA cluster) and the miR-371-3 cluster are located on chromosome 19 and were involved in stem cell biology 
and tumorigenesis53,54. The miRNAs in the miR-371-3 cluster were biomarkers for TGCT2,46,47. In addition, the 
miR-141/200c cluster, which is part of the miR-200 family, has been reported to be associated with breast cancer55, 
whereas miR-200c-3p was found to be associated with TGCT47.
Eight TGCT-related miRNAs (miR-200c-3p, miR-302a-3p, miR-302c-3p, miR-302d-3p, miR-367-3p, miR-
372-3p, and miR-373-3p) were hubs in both the NSE and SE-specific regulatory networks. Because we have 
determined the differences between the two types of TGCT, we next investigated whether there were common 
properties in regulation. We identified some common FFLs in NSE and SE, as shown in Fig. 2. A common TRF 
was NANOG—miR-373-3p—FRMD4A, in which NANOG was also a biomarker (and a TF) in TGCT56; hence 
this FFL might have crucial roles in TGCT tumorigenesis. There were 8 common TAFs that included 4 TFs (ERG, 
JUN, SOX9, and NR2F2), 4 miRNAs (miR-302a-3p, miR-302d- 3p, miR-367-3p, and miR-373-3p) and 5 target 
CTTNBP2RND3
TIMP3
FRMD4A
PALLD TIMP3TNS1
NR2F2
miR-302d-3pmiR-302a-3p
SOX9ERG
miR-373-3p
miR-367-3p
NANOG
JUN
miR-302a-3p
NR2F2
miR-373-3p
miR-302d-3p miR-373-3p
MRFTRF TAF
Figure 2. Cytoscape networks of Common FFLs in NSE and SE. (Cytoscape version 3.7.1, https://cytoscape.
org/).
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genes (CTTNBP2, PALLD, RND3, TIMP3, and TNS1). In addition, there were 3 MRFs that shared the same TF 
and target gene: NR2F2—miR-302a-3p/302d-3p/373-3p—TIMP3.
Enrichment analysis of genes in subtype-specific regulatory networks. We conducted path-
way enrichment analysis of the genes from TGCT subtype-specific regulatory networks by using Kyoto 
Encyclopedia of Genes and Genomes (KEGG)57 pathway annotations and WebGestalt tool58. By setting FDR 
(Benjamini-Hochberg adjusted p-value) threshold 0.05, we identified 4 oncogenic pathways that were signif-
icantly over-represented in both NSE and SE subtypes from the top 10 pathways (Table 3). Furthermore, Wnt 
signaling (FDR = 0.007), and Calcium signaling (FDR = 0.013) were significantly enriched in NSE subtype57. Of 
note, TGCT is male-specific cancer. For the SE subtype, we observed several relevant pathways were enriched 
in the context of TGCT, including Transcriptional dysregulation in cancer (FDR = 0.011), and Jak-STAT signa-
ling (FDR = 0.017) pathways. The Jak-STAT signaling pathway is a well-known oncogenic and stemness-related 
pathway.
Regulatory features of Yamanaka factors in TGCT subtypes. Yamanaka factors include four tran-
scription factors [KLF4, MYC, POU5F1 (OCT3/OCT4), and SOX2]. They are highly expressed in embryonic 
stem cells. The imbalanceness in their expression (e.g., over-expression) can induce pluripotency in both mouse 
and human somatic cells59,60. The expression of Yamanaka factors have previously been detected in testicular 
cancer61. In addition, two TF-coding genes (POU5F1 and SOX2) are candidate biomarkers in TGCT56. Their roles 
have been reported in testicular cancer7,8. This motivated us to explore the regulatory features of the Yamanaka 
factors in two TGCT subtypes: NSE and SE.
First, all the four Yamanaka factors were expressed in both NSE and SE, but they had different regulatory 
patterns. SOX2 and MYC were up-regulated in NSE, whereas POU5F1 and KLF4 had down-regulation. Second, 
Subtype Pathway Description p-value FDR # informative genes
NSE
hsa04550 Signaling pathways regulating pluripotency of stem cells 1.11E-06 0.0002 10
hsa05166 HTLV-I infection 1.12E-06 0.0002 13
hsa04310 Wnt signaling pathway 7.54E-05 0.0070 8
hsa04950 Maturity onset diabetes of the young 0.0001 0.0070 4
hsa05200 Pathways in cancer 0.0001 0.0070 13
hsa05205 Proteoglycans in cancer 0.0002 0.0086 9
hsa04380 Osteoclast differentiation 0.0003 0.0130 7
hsa05210 Colorectal cancer 0.0003 0.0130 5
hsa04020 Calcium signaling pathway 0.0004 0.0134 8
hsa05224 Breast cancer 0.0006 0.0170 7
hsa04510 Focal adhesion 0.0008 0.0227 8
hsa04022 cGMP-PKG signaling pathway 0.0013 0.0324 7
hsa05213 Endometrial cancer 0.0017 0.0357 4
hsa04360 Axon guidance 0.0017 0.0357 7
hsa05215 Prostate cancer 0.0018 0.0357 5
hsa04974 Protein digestion and absorption 0.0019 0.0357 5
hsa05217 Basal cell carcinoma 0.0021 0.0366 4
hsa04916 Melanogenesis 0.0031 0.0498 5
hsa04933 AGE-RAGE signaling pathway in diabetic complications 0.0031 0.0498 5
SE
hsa04658 Th1 and Th2 cell differentiation 1.68E-06 0.0005 8
hsa05166 HTLV-I infection 3.16E-06 0.0005 12
hsa05200 Pathways in cancer 1.10E-05 0.0011 14
hsa05321 Inflammatory bowel disease (IBD) 2.60E-05 0.0020 6
hsa05161 Hepatitis B 5.14E-05 0.0031 8
hsa05202 Transcriptional misregulation in cancer 0.0002 0.0106 8
hsa05210 Colorectal cancer 0.0002 0.0106 5
hsa05224 Breast cancer 0.0004 0.0135 7
hsa05205 Proteoglycans in cancer 0.0005 0.0174 8
hsa04630 Jak-STAT signaling pathway 0.0006 0.0174 7
hsa04350 TGF-beta signaling pathway 0.0010 0.0274 5
hsa04380 Osteoclast differentiation 0.0013 0.0321 6
hsa04550 Signaling pathways regulating pluripotency of stem cells 0.0019 0.0432 6
hsa04320 Dorso-ventral axis formation 0.0021 0.0447 3
hsa05216 Thyroid cancer 0.0023 0.0463 3
Table 3. Pathways enrichment analysis of the genes in subtype-specific regulatory networks by WebGestalt 
(FDR < 0.05). FDR: false discovery rate.
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the number of regulation pairs of these four factors varied. KLF4 and MYC had high degree in the network (3 
and 6 folds, respectively) in SE, while SOX2 had high degree (3 folds) in NSE (Fig. 3A). Finally, we explored 
the FFLs containing these TFs. Only POU5F1 and KLF4 formed FFLs in the NSE regulatory network; all these 
FFLs were TRFs, indicating that their target genes were repressed by POU5F1 and KLF4. We integrated these 
FFLs to construct a dense subnetwork, which consisted of 7 miRNAs, 2 TFs, 8 genes, and 41 regulations. The 
seven miRNAs included miR-182-5p, miR-519d-3p, and 5 miR-520a-e. For SE, we found 3 TFs (KLF4, MYC, and 
POU5F1) formed 52 FFLs. Similar to NSE, the majority of these FFLs (40 out of 52) were TRFs. KLF4, MYC, and 
POU5F1formed FFLs, which were integrated into two dense subnetworks. In the network, KLF4 positively regu-
lated 11 miRNAs and 4 genes, but negatively regulated 2 miRNAs and 23 genes. We observed 4 of the 5 TRFs and 
all of the 4 MRFs constituted 4 FFLs, in which KLF4 and miR-29b-3p repressed each other and regulated their 
common target genes (CRISPLD1, EML5, MEX3B, and SLC16A1). MYC involved in three FFLs, MYC—miR-
182-5p—CITED2, MYC—miR-182-5p—ZFP36L1, and MYC—miR-183-5p—ZFP36L1, all of which were MRFs. 
POU5F1 only formed one FFL (POU5F1—miR-25-3p—DUSP6), which was a TRF. Several miRNAs, including 
miR-141-3p, miR-182-5p, miR-183-5p, miR-25-3p, miR-519d-3p, and miR-520, as well as TGCT-related miRNAs 
were involved in this subnetwork (Fig. 3B–D).
Subtype prediction based on top FFLs. For NSE and SE, we applied Random Forest classifier to each 
of the top 5 FFLs belonging to each FFL category to classify corresponding experimental or control class label 
(e.g., NSE or SE here). Using 10-fold cross-validation with 10 repeats, we obtained the classification performance 
on the samples for each FFL. In our experiment, the majority of the FFLs provided high classification accuracy 
(>= 90%) and area under the curve (AUC) (>0.9). For example, the FFL (TFAP2C—miR-520d-3p—LYPD6) in 
the category of NSE TRF produced the highest average accuracy (0.991) as well as the highest AUC (>0.999). FFL 
ARID5B—miR-367-3p—STARD13 in the category of NSE MRF generated the second highest average accuracy 
(0.982) as well as the second highest AUC (0.999). FFL NR2F2—miR-141-3p—EPHA2 in the category of SE TAF 
had the third highest average accuracy (0.979) as well as the third highest AUC (0.998). The details of average 
sensitivity, average specificity, average precision, average accuracy and AUC scores for the top 5 FFLs of each 
category are summarized in Supplementary Fig. S3, Supplementary Fig. S4, and Table 4. Since these hub genes in 
top 5 FFLs were important for the regulatory mechanism of TGCT, we evaluated their regulatory patterns using a 
validation dataset (GEO GSE99420)62 below.
Subtype-specific hub regulators and targets for NSE. There were 2 TFs (NR2F1 and NR2F2), 7 miR-
NAs (miR-367-3p, miR-519d-3p, miR-520b, miR-520c-3p, miR-520d-3p miR-520e, and miR-96-5p,) and 1 gene 
(DCAF5) identified as hubs in the top 5 FFLs that were specific for NSE. Only 2 TF-coding genes (NR2F1 and 
NR2F2) and 3 miRNAs (miR-367-3p, miR-519d-3p, and miR-96-5p) were expressed in the GEO dataset, and 
their expression patterns were represented in Fig. 4. All these five genes represented the same regulatory pat-
terns in TCGA and GEO datasets (see Supplementary Table S3). Specifically, two miRNAs (miR-96-5p, and miR-
367-3p) were up-regulated, whereas the other miRNA is down-regulated. Both of the two TFs were up-regulated 
in NSE subtype.
Figure 3. Feed forward loops (FFLs) related to Yamanaka factors. (A) Number of regulations of four Yamanaka 
factors in each TGCT subtype. (B) Number of FFLs in each subcategory (TRF, TAF, and MRF). (C) Cytoscape 
networks of NSE subtype-specific regulatory network. (D) Cytoscape networks of SE subtype-specific 
regulatory network. (Microsoft Excel 2013; Cytoscape version 3.7.1, https://cytoscape.org/).
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Subtype-specific hub regulators and targets for SE. For SE, there were 4 TFs (GATA3, JUN, KLF4, 
and SPI1), 5 miRNAs (miR-141-3p, miR-200c-3p, miR-25-3p, miR-29b-3p, and miR-302a-3p), and 4 genes 
(EPHA2, PLXDC2, RND3, and TIMP3) expressed in both TCGA and GEO datasets (Fig. 4 and Supplementary 
Table S3). Among the 5 miRNAs, 3 showed the same regulatory pattern in the two datasets, i.e., miR-200c-3p, 
and miR-302a-3p were down-regulated and miR-25-3p was up-regulated. In TCGA dataset, miR-141-3p was 
down-regulated and miR-29b-3p was up-regulated, whereas in the GEO dataset, these two miRNAs showed sim-
ilar expression levels for both NSE and SE. Of note, miR-200c-3p and miR-302a-3p had stronger molecular sig-
natures when compared to miR-25-3p in SE. Since the TFs were the top four hubs according to their out-degrees 
ranked from high to low score, they might play vital roles in regulating targets. JUN was down-regulated and 
KLF4 and SPI1 were up-regulated in both of the two datasets, even though SPI1 was slightly up-regulated in the 
GEO dataset. While GATA3 was down-regulated in TCGA dataset, it was slightly up-regulated in the GEO data-
set. Hence, JUN and KLF4 were likely reliable molecular signatures for SE samples. All four hub genes (EPHA2, 
PLXDC2, RND3, and TIMP3) were down-regulated in both datasets. By exploring the FFLs in which these hub 
genes were involved (Supplementary Table S2), we determined that they were regulated by several hub TFs, 
including SPI1, KLF4, JUN, GATA3, NR2F2, and SOX9. The miRNAs included miR-302a/d-3p, miR-372/373-3p, 
miR-520a-e, and miR141/200c, all of which have been discussed above.
NR2F2. Interestingly, we observed that a specific TF-coding gene, NR2F2 (nuclear receptor subfamily 2 group 
F member 2) was in 7 of 15 top-five FFLs (Table 4), and a key gene for classifying the NSE subtype. We investi-
gated the FFLs in which NR2F2 was involved, and determined that TF NR2F2 formed TAFs and MRFs with hub 
miRNAs (e.g., miR302-a/d-3p, miR372/373-3p, miR-519d-3p, miR520-a-e, and miR-96-5p), suggesting that it 
might be critical in NSE (Fig. 5A). We also determined that this TF was in 4 out of 15 top five FFLs for SE, and in 7 
of 15 FFLs for NSE (Table 4). As shown in Fig. 5B, NR2F2 and hub miRNAs (e.g. miR302-a/d-3p, miR373-3p, and 
miR-141/200c-3p) regulated common target genes, including two hub genes (EPHA2 and TIMP3). According to 
the literature, NR2F2 was overexpressed in ovarian cancer and prostate cancer, and its dysregulation was associ-
ated with testis developmental defects63,64, uterine fibroids65, and uterine implantation failure66. Taken together, 
NR2F2 is likely a promising candidate gene in TGCT, especially in NSE.
Top five FFLs Elements in the FFL(TF, miRNA, gene) Avg. sensitivity Avg. specificity Avg. precision Avg. accuracy
NSE TRF FFL1 MAFA, miR-519d-3p, MCF2L 0.98 0.96 0.96 0.97
FFL2 NANOG, miR-520e, DCAF5 0.94 0.96 0.95 0.95
FFL3 MAFA, miR-96-5p, ARHGAP24 0.98 0.96 0.95 0.97
FFL4 TFAP2C, miR-520d-3p, LYPD6 0.98 1.00 1.00 0.99
FFL5 TFAP2C, miR-519d-3p, LYPD6 0.98 1.00 1.00 0.99
NSE TAF FFL1 NR2F2, miR-96-5p, ARHGAP24 0.61 0.77 0.70 0.70
FFL2 NR2F2, miR-96-5p, SPATS2L 0.63 0.75 0.68 0.69
FFL3 NR2F1, miR-96-5p, SPATS2L 0.65 0.77 0.71 0.71
FFL4 NR2F2, miR-520e, DCAF5 0.94 0.92 0.91 0.93
FFL5 NR2F2, miR-520d-3p, DCAF5 0.95 0.91 0.90 0.93
NSE MRF FFL1 ARID5B, miR-367-3p, NFIX 0.97 0.97 0.96 0.97
FFL2 NR2F2, miR-520e, DCAF5 0.94 0.92 0.91 0.93
FFL3 NR2F2, miR-520b, DCAF5 0.95 0.91 0.90 0.93
FFL4 NR2F2, miR-520c-3p, DCAF5 0.94 0.91 0.90 0.93
FFL5 ARID5B, miR-367-3p, STARD13 0.98 0.98 0.98 0.98
SE TRF FFL1 SPI1, miR-338-3p, ZBTB39 0.86 0.94 0.92 0.90
FFL2 KLF4, miR-200c-3p, RND3 0.88 0.96 0.95 0.92
FFL3 SPI1, miR-142-5p, ULK1 0.90 0.96 0.95 0.93
FFL4 SPI1, miR-29b-3p, CSPG4 0.62 0.71 0.65 0.67
FFL5 SPI1, miR-29b-3p, MEX3B 0.85 0.90 0.88 0.87
SE TAF FFL1 SPI1, miR-373-3p, PLXDC2 0.83 0.92 0.90 0.87
FFL2 JUN, miR-200c-3p, RND3 0.89 0.96 0.96 0.93
FFL3 SPI1, miR-141-3p, HNMT 0.94 0.93 0.92 0.93
FFL4 NR2F2, miR-141-3p, EPHA2 0.98 0.98 0.98 0.98
FFL5 SPI1, miR-25-3p, FAM20C 0.91 0.92 0.91 0.92
SE MRF FFL1 JUN, miR-200c-3p, RND3 0.89 0.96 0.96 0.93
FFL2 GATA3, miR-141-3p, HNMT 0.89 0.93 0.92 0.91
FFL3 NR2F2, miR-302d-3p, EPHA2 0.96 0.98 0.98 0.97
FFL4 NR2F2, miR-302a-3p, TIMP3 0.95 0.91 0.91 0.93
FFL5 NR2F2, miR-302a-3p, EPHA2 0.97 0.96 0.96 0.97
Table 4. Subtype classification performance using top five FFLs of each category.
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Common regulators and genes in two TGCT subtypes. When comparing SE-specific and NSE-specific 
network, we found 9 common molecules including five miRNAs (miR-182-5p, miR-302a-3p, miR-367-3p, miR-
372-3p, and miR-96-5p), one TF-coding gene (JUN), and three non-TF genes (FRMD4A, PALLD, and TNS1). Of note, 
the out-degrees of miR-96-5p in SE- and NSE-networks were 11 and 38, respectively, whereas the in-degrees were 6 
and 17, respectively. For miR-182-5p, the corresponding values of out-degrees for SE and NSE networks were 11 and 
33, respectively, whereas the in-degrees were 5 and 14, respectively. The details were summarized in Supplementary 
Table S1. The adjusted p-values for these 5 miRNAs for SE and NSE analysis were 9.08 × 10−9, 1.69 × 10−10, 4.18 × 10−7, 
2.74 × 10−6, and 1.38 × 10−3, respectively. For TF JUN, it had out-degree 29 and 26, respectively, in the SE and NSE 
networks, and in-degree 2 and 0, respectively. The p-value of JUN for SE and NSE analysis was 3.17 × 10−14.
Discussion
So far, studies have been conducted to characterize the genetic, epigenetic, and molecular mechanisms of TGCT2–4,6,7, 
but not much in regulatory investigation. In this study, we first identified TGCT subtype-specific differen-
tially expressed genes (mRNA and miRNA)35,36. Next, we collected TF-target gene pairs using TRANSFAC and 
miRNA-target gene pairs using four miRNA-target curation databases. Then, we formed FFLs by three categories: 
TRFs, TAFs, and MRFs. These FFLs were further used to build TF-miRNA-target gene regulatory network in two 
TGCT subtypes (NSE and SE). Our network analyses (such as detecting the hub nodes for TFs, miRNAs, and 
genes) and subtype classification analyses pinpointed subset of the FFLs that might have a significant role in the 
pathogenesis of TGCT subtypes. The TFs, miRNAs, and genes in the top FFLs represented promising molecular 
signatures in classifying TGCT types. From the dysregulated FFL networks, we assessed that most of the top FFLs 
could generate higher than 90% average subtype-classification accuracy through Random Forest classifier. Our 
study generated several SE-specific dysregulated miRNAs (miR-200c-3p, miR-25-3p, miR-302a-3p), SE-specific 
dysregulated genes (EPHA2, JUN, KLF4, PLXDC2, RND3, SPI1, and TIMP3), NSE-specific dysregulated miR-
NAs (miR-367-3p, miR-519d-3p, and miR-96-5p) and NSE-specific dysregulated genes (NR2F1 and NR2F2). 
Furthermore, we validated the hub molecules using an independent dataset for TGCT. The validation analysis 
indicated that they had the similar expression patterns. Our FFL based analysis could identify distinct regulatory 
molecules, their interaction modules, and other features in two TGCT subtypes.
Figure 4. Evaluation of the hub microRNAs and genes in top FFLs by an independent dataset (GEO 
GSE99420). (A) NSE subtype. (B) SE subtype. On the y-axis, expression level was measured by transformed 
RSEM normalized count. (RStudio version 1.1.383, https://rstudio.com/).
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One important limitation of the study is that the dataset did not include matched control samples. This limi-
tation was due to the original TGCT study by The Cancer Genome Atlas (TCGA), which represented the largest 
dataset in the field. Therefore, our results only represented the difference in expression and regulation between 
the two TGCT subtypes, not between TGCT tumors versus controls. Future work should include a more com-
prehensive understanding of the regulatory mechanisms to further uncover complex diseases like TGCT using 
additional multiple omics data (e.g., methylation and copy number) and regulatory relations (e.g., enhancer-gene 
associations). The analytical approaches proposed in this study can be applied to similar data in other cancers or 
complex diseases.
Materials and Methods
Clinical information. We downloaded TCGA generated TGCT patients’ clinical pathological information 
deposited in Xena database (https://xenabrowser.net/datapages, Accessed date: October 20, 2017). There was a 
total of 156 samples in the original clinical data file. We filtered the samples by the following two conditions as in 
our previous study10: (1) the age range of the patients was between 18 and 45; and (2) all the samples belonged to 
NSE or SE were verified histologically. This resulted in 48 NSE samples and 55 SE samples.
Subtype-specific differentially expressed genes and miRNAs. Both the mRNA and miRNA expres-
sion profiles for the TGCT patient samples were downloaded from TCGA. We filtered the genes and miRNAs 
using the same procedure as in our previous study10. Briefly, for gene expression profile, we removed the genes 
having a log2-transformed RSEM expression level less than 1 in more than 50% of the samples10,67. For miRNA 
expression profiles, we removed the miRNAs with missing values in more than 10% of the samples, and only 
retained those miRNAs that had log2-transformed RSEM expression levels greater than 3.46 in more than 10% 
of the samples10,68.
Since the matched normal samples were unavailable in TCGA, we identified the differentially expressed 
genes and miRNAs between NSE and SE using statistical tool Limma implemented in R package35,36. A gene (or 
miRNA) was considered differentially expressed in NSE samples versus SE samples if they had at least 2-fold 
change with the adjusted p-value < 0.05. The same applied in the comparison of SE versus NSE. The analysis iden-
tified 2,950 genes and 167 miRNAs that were significantly highly expressed in NSE samples (i.e., NSE versus SE) 
and 1,969 genes and 58 miRNAs significantly highly expressed in SE samples (SE versus NSE).
Transcriptional regulations of TF-gene and TF-miRNA. TRANSFAC is a comprehensive TF-target 
relation database37. We identified TF-gene pairs and TF-miRNA pairs according to the pipeline in previous stud-
ies15,18 using TRANSFAC data (release April 6, 2016). First, we retrieved the promoter region sequences, ranging 
from −1500 to +500 bp around each transcription start site (TSS) of human genes and miRNAs obtained from 
UCSC Table Browser69. We employed MATCH software38 to find the binding sites. We applied a pre-calculated 
stringent threshold to create a high-quality matrix, and we required a core score of 1.00 and a matrix score of 0.95 
for each pair. Moreover, we only selected those TF-gene pairs that were conserved among human, mouse and rat.
Post-transcriptional regulations of miRNA-gene and miRNA-TF. We selected three reliable 
miRNA-target prediction databases, TargetScan39 (release 7.1, June 2016), miRanda40 (release August 2010), and 
PITA41 (release Thursday, December 09, 2010). Furthermore, we regarded miRNA-target pairs from miRTar-
Base42 (release 7.0, September 15, 2017) in which the data were curated from low and high-throughput exper-
imental procedures. We retained the pairs if they were present in at least two databases, which resulted in the 
identification of 170,544 miRNA-target pairs having a total of 697 unique miRNAs and a total of unique 12,507 
target genes. Among them, a subset of the target genes was denoted as TFs.
Significant transcriptional and post-transcriptional regulations. Before evaluating FFLs in regu-
latory networks, we defined significant regulations in our study using Pearson's correlation coefficient (PCC) 
Figure 5. Cytoscape networks of Subtype-specific subnetwork concerning NR2F2. (A) NSE. (B) SE. (Cytoscape 
version 3.7.1, https://cytoscape.org/).
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threshold and corresponding p-value threshold (0.05). In biology, TFs may either activate or repress their target 
genes, and miRNAs typically repress their target genes. Accordingly, we evaluated the positive and negative cor-
relation to determine TF-gene/miRNA pairs, but only negative correlation to determine miRNA-gene/TF pairs. 
By applying the threshold values above, we identified 18,431 significant regulation pairs using the data from NSE, 
but 7,447 significant regulation pairs in the SE subtype. Considering that PCC threshold values varied in literature 
and the pairs were candidate for further network analysis, we used PCC > 0.6 for NSE. This reduced the number 
of regulation pairs to 6,930, which is similar to SE.
FFLs in NSE and SE. Since FFLs are directional, reflecting specific biological regulation, we define FFLs by 
three subcategories: TF represses FFLs (TRFs), TF activates FFLs (TAFs), and miRNA represses FFLs (MRFs). 
In the TRF model, a TF activates its target miRNA to repress a target gene indirectly, whereas the same TF also 
represses the same target gene directly. In the TAF model, a TF represses its target miRNA to repress a target gene 
indirectly, whereas the same TF activates the same target gene directly overcoming the effect of suppression by 
the target miRNA. In the MRF model, a miRNA represses its target TF to repress a target gene indirectly, whereas 
the same miRNA represses the same target gene directly. Of note, these three models represent biologically coher-
ent FFLs43. In this study, we formed FFLs from the significantly correlated regulator-target pairs in NSE and SE, 
separately.
Subtype-specific regulatory network construction and analysis. TGCT type-specific regulatory 
networks were constructed through integrating the identified FFLs in NSE and SE. We examined common and 
distinct properties between these two networks. We visualized the networks using Cytoscape, the network visu-
alization software (version 3.7.1, https://cytoscape.org/)70,71. We analyzed the topological properties of the regu-
latory networks with Cytoscape plugin and identified hubs49.
Validate of hub molecules. The expression patterns of three types of molecules (TF, miRNA and gene) 
identified as hubs were evaluated using an independent dataset from GEO (ID: GSE99420)62. The original study 
was to find gene signatures for relapse after 2 and 3 years of surveillance of TGCT. It had all the samples belonged 
to stage I, and could be divided into relapse or non-relapse, as well as NSE versus SE. The expression data was 
generated by Expression profiling by array platform. We used expression of 30 NSE and 30 SE samples from this 
dataset.
Subtype classification based on top FFLs. To evaluate the classification ability of the resultant FFLs in 
terms of sample classification, we selected the top five FFLs from each category of FFL in NSE and SE subtype, 
individually. All the participating biomolecules (TF, miRNA and gene) belonging to each FFL were then used 
as features to perform two-class classification on the samples of the data using Random Forest classifier using R 
package caTools72. We utilized five measures [sensitivity, specificity, precision, accuracy, area under the receiver 
operating characteristic curve (AUC)] to evaluate the performance36. For a confusion matrix, there are basi-
cally four types in metrics: TP (True Positive), FN (False Negative), FP (False Positive) and TN (True Negative). 
Sensitivity denotes true positive rate, i.e., the proportion of actual positive test set tuples which are correctly 
classified. In other words, sensitivity is the fraction of true positives to the total number of true positives and false 
negatives.
=
+
TP
TP FN
Sensitivity
(1)
Specificity is the true negative rate i.e., the proportion of actual negative test set tuples which are correctly 
classified. In other words, specificity is the fraction of true negatives to the total number of true negatives and 
false positives.
=
+
TN
TN FP
Specificity
(2)
Accuracy is the proportion of all actual positive and negative test set tuples which are correctly classified, i.e., 
the fraction of the total number of true positives and true negatives to the total numbers of true positives, true 
negatives, false positives and false negatives.
=
+
+ + +
TP TN
TP TN FP FN
Accuracy
(3)
Precision is the positive predictive rate, i.e., the fraction of the retrieved test tuples that are relevant. In other 
words, precision is the fraction of the true positives to the total number of true positives and false positives.
=
+
TP
TP FP
Precision
(4)
For the experiment, we applied 10-fold cross-validation by repeating 10 times. Finally, we computed the aver-
age score of each evaluation metric.
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